Brought to you by 
Archimedes grants Lazanda rights to Depomed
30 Jan 2023
Executive Summary
Archimedes Pharma Ltd. (therapies for pain, cancer, neurology, and critical care) has licensed spec pharma Depomed Inc. exclusive rights to sell its breakthrough cancer pain treatment Lazanda (fentanyl) in the US and Canada.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Archimedes grants Lazanda rights to Depomed
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice